
Craig L Slingluff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5585101/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A pilot trial of vaccination with <scp>Carcinoembryonic antigen</scp> and Her2/neu peptides in advanced colorectal cancer. International Journal of Cancer, 2022, 150, 164-173.	5.1	5
2	The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling. , 2022, 10, e003533.		7
3	Melanoma trials that defined surgical management: Overview of trials that established NCCN margin guidelines. Journal of Surgical Oncology, 2022, 125, 28-33.	1.7	1
4	An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes. Cancer Cell, 2022, 40, 524-544.e5.	16.8	23
5	Patterns of Recurrence and Prognosis in Pathologic Stage I and II Merkel Cell Carcinoma: A multi-center, retrospective cohort analysis. Journal of the American Academy of Dermatology, 2022, , .	1.2	0
6	PRAME expression in 155 cases of metastatic melanoma. Journal of Cutaneous Pathology, 2021, 48, 479-485.	1.3	37
7	Multiplex Immunofluorescence Histology for Immune Cell Infiltrates in Melanoma-Associated Tertiary Lymphoid Structures. Methods in Molecular Biology, 2021, 2265, 573-587.	0.9	7
8	Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials. Cancer Immunology, Immunotherapy, 2021, 70, 2151-2164.	4.2	6
9	Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells. Cancer Immunology Research, 2021, 9, 583-597.	3.4	9
10	Childhood cancer survivors face markedly worse overall survival after diagnosis with breast cancer, melanoma, or colorectal cancer. Journal of Surgical Oncology, 2021, 124, 16-24.	1.7	0
11	Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. Annals of Surgical Oncology, 2021, 28, 6995-7003.	1.5	8
12	Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma. JCO Precision Oncology, 2021, 5, 589-601.	3.0	20
13	Isolated same-basin lymph node recurrence after precision lymph node excision for clinically evident melanoma metastasis Journal of Clinical Oncology, 2021, 39, 9576-9576.	1.6	0
14	Randomized multicenter phase lb/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer Journal of Clinical Oncology, 2021, 39, 4128-4128.	1.6	11
15	Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist. , 2021, 9, e002214.		11
16	Retargeting IL-2 Signaling to NKG2D-Expressing Tumor-Infiltrating Leukocytes Improves Adoptive Transfer Immunotherapy. Journal of Immunology, 2021, 207, 333-343.	0.8	5
17	Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma. , 2021, 9, e002273.		39
18	Myeloid Cell Infiltration Correlates With Prognosis in Cholangiocarcinoma and Varies Based on Tumor Location. Journal of Immunotherapy, 2021, 44, 254-263.	2.4	6

#	Article	IF	CITATIONS
19	Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Reports, 2021, 36, 109422.	6.4	89
20	Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163+ myeloid cell infiltrates. Journal of Translational Medicine, 2021, 19, 371.	4.4	9
21	Phospho-β-catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2. Pathology Research and Practice, 2021, 224, 153527.	2.3	2
22	Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients. Cancer Immunology Research, 2021, 9, 1327-1341.	3.4	4
23	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma. , 2021, 9, e003220.		20
24	Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. , 2021, 9, e003272.		6
25	Immunotyping and Quantification of Melanoma Tumor–Infiltrating Lymphocytes. Methods in Molecular Biology, 2021, 2265, 515-528.	0.9	2
26	Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63). , 2021, 9, e000934.		14
27	A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Oncolmmunology, 2021, 10, 1898105.	4.6	11
28	IDO1 Expression in Melanoma Metastases Is Low and Associated With Improved Overall Survival. American Journal of Surgical Pathology, 2021, 45, 787-795.	3.7	6
29	Proliferating CD8+ T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma. Cells, 2021, 10, 3378.	4.1	24
30	Flexible Phase I–II Design for Partially Ordered Regimens with Application to Therapeutic Cancer Vaccines. Statistics in Biosciences, 2020, 12, 104-123.	1.2	3
31	Comparative Effectiveness of Lymphadenectomy Strategies During Curative Resection for Gastric Adenocarcinoma. Journal of Gastrointestinal Surgery, 2020, 24, 2212-2218.	1.7	Ο
32	Tailoring early-phase clinical trial design to address multiple research objectives. Cancer Immunology, Immunotherapy, 2020, 69, 95-102.	4.2	4
33	Building on the Promise of Cancer Vaccines for Solid Tumors. Clinical Cancer Research, 2020, 26, 529-531.	7.0	7
34	Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. Cardio-Oncology, 2020, 6, 21.	1.7	14
35	Peritoneal Cell-Free Tumor DNA as Biomarker for Peritoneal Surface Malignancies. Annals of Surgical Oncology, 2020, 27, 5065-5071.	1.5	14
36	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15

#	Article	IF	CITATIONS
37	Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues. Scientific Reports, 2020, 10, 18336.	3.3	6
38	MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma. , 2020, 8, e000262.		44
39	Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. , 2020, 8, e000544.		13
40	Deconvolution of the immunological contexture of mouse tumors with multiplexed immunohistochemistry. Methods in Enzymology, 2020, 635, 81-93.	1.0	3
41	<p>Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data</p> . Breast Cancer: Targets and Therapy, 2020, Volume 12, 69-75.	1.8	10
42	Evaluation of camera-based freehand SPECT in preoperative sentinel lymph node mapping for melanoma patients. EJNMMI Research, 2020, 10, 139.	2.5	14
43	Final analysis of relapse-free survival in a multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine after resection of high-risk melanoma Journal of Clinical Oncology, 2020, 38, 10017-10017.	1.6	6
44	Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis. Annals of Surgical Oncology, 2019, 26, 3962-3971.	1.5	5
45	A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients. , 2019, 7, 163.		59
46	Vaccine Strategy in Melanoma. Surgical Oncology Clinics of North America, 2019, 28, 337-351.	1.5	17
47	Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8 ⁺ T cells. Science Immunology, 2019, 4, .	11.9	95
48	Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors. Cancer Immunology, Immunotherapy, 2019, 68, 1121-1132.	4.2	13
49	Bariatric surgery is independently associated with a decrease in the development of colorectal lesions. Surgery, 2019, 166, 322-326.	1.9	17
50	Systems analysis of barrier molecule and ARNT-related gene expression regulation in melanoma. Oncolmmunology, 2019, 8, e1665978.	4.6	6
51	The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis. Annals of Surgery, 2019, 270, 712-722.	4.2	14
52	Updates in adjuvant systemic therapy for melanoma. Journal of Surgical Oncology, 2019, 119, 222-231.	1.7	35
53	CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clinical Cancer Research, 2018, 24, 1415-1425.	7.0	73
54	Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. Journal of Immunology, 2018, 200, 432-442.	0.8	153

#	Article	IF	CITATIONS
55	Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Research, 2018, 28, 237-245.	1.2	35
56	Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?. Cancer Immunology, Immunotherapy, 2018, 67, 161-174.	4.2	24
57	Academic or community practice? What is driving decision-making and career choices. Surgery, 2018, 164, 571-576.	1.9	11
58	Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma. Oncolmmunology, 2018, 7, e1490855.	4.6	10
59	Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma Journal of Clinical Oncology, 2018, 36, 3033-3033.	1.6	5
60	Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFmM): Implications for combination with immunotherapy Journal of Clinical Oncology, 2018, 36, 9559-9559.	1.6	3
61	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists for resected stage IIB-IV melanoma Journal of Clinical Oncology, 2018, 36, e15171-e15171.	1.6	2
62	Mismatch repair deficiency in cholangiocarcinoma Journal of Clinical Oncology, 2018, 36, 269-269.	1.6	5
63	Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget, 2018, 9, 8972-8984.	1.8	3
64	Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma Journal of Clinical Oncology, 2018, 36, e15175-e15175.	1.6	0
65	Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study. Annals of Surgical Oncology, 2017, 24, 2728-2733.	1.5	27
66	Peptide Vaccine: Overview. , 2017, , 427-439.		1
67	The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity?. Melanoma Research, 2017, 27, 211-217.	1.2	22
68	Surgery investigators funded through the National Institutes of Health: A rebirth. Surgery, 2017, 161, 1482-1488.	1.9	13
69	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell, 2017, 171, 934-949.e16.	28.9	1,515
70	Vaccines targeting helper T cells for cancer immunotherapy. Current Opinion in Immunology, 2017, 47, 85-92.	5.5	145
71	Heterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact onÂpatient prognostic assessments and comparison of quantification by different sampling strategies. Cancer Immunology, Immunotherapy, 2017, 66, 33-43.	4.2	30
72	Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. Journal of Hematology and Oncology, 2017, 10, 152.	17.0	63

5

#	Article	IF	CITATIONS
73	A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer. , 2017, 5, 92.		47
74	Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies. Journal of Translational Medicine, 2017, 15, 180.	4.4	8
75	Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer Journal of Clinical Oncology, 2017, 35, 4125-4125.	1.6	10
76	Salvage combination ipilimumab and nivolumab after failure of prior checkpoint inhibitor therapy in patients with advanced melanoma Journal of Clinical Oncology, 2017, 35, e21009-e21009.	1.6	4
77	Phase 1/2 study of in situ vaccination with tremelimumab + intravenous (IV) durvalumab + poly-ICLC in patients with select relapsed, advanced cancers with measurable, biopsy-accessible tumors Journal of Clinical Oncology, 2017, 35, TPS3106-TPS3106.	1.6	3
78	Effect of gene expression profile (GEP) testing on clinical management in 19% of consecutively treated patients with stage IB/IIA melanoma at a single institution Journal of Clinical Oncology, 2017, 35, e21080-e21080.	1.6	1
79	Interim analysis of survival outcomes in a prospective cohort evaluating a prognostic 31-gene expression profile (GEP) test for melanoma Journal of Clinical Oncology, 2017, 35, 9573-9573.	1.6	0
80	Correlation of mesothelin expression and CD8 tumor infiltrating lymphocytes with prognosis in cholangiocarcinoma Journal of Clinical Oncology, 2017, 35, e15650-e15650.	1.6	0
81	Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature. , 2016, 4, 94.		91
82	Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. OncoImmunology, 2016, 5, e1240857.	4.6	56
83	Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. Oncolmmunology, 2016, 5, e1160193.	4.6	11
84	Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. Immunotherapy, 2016, 8, 583-600.	2.0	71
85	PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. Oncolmmunology, 2016, 5, e1235107.	4.6	104
86	Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. EBioMedicine, 2016, 10, 85-100.	6.1	56
87	Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. Cancer Immunology, Immunotherapy, 2016, 65, 1189-1199.	4.2	38
88	Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. Cancer Immunology, Immunotherapy, 2016, 65, 1201-1212.	4.2	36
89	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2016, 17, 943-955.	10.7	293
90	From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. , 2016, 4, 14.		101

#	Article	IF	CITATIONS
91	A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites. Cancer Immunology, Immunotherapy, 2016, 65, 25-36.	4.2	30
92	Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. Journal of Clinical Investigation, 2016, 126, 921-937.	8.2	71
93	Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064) Journal of Clinical Oncology, 2016, 34, 9517-9517.	1.6	1
94	Long-term Outcomes of Helper Peptide Vaccination for Metastatic Melanoma. Annals of Surgery, 2015, 262, 456-464.	4.2	26
95	Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials' experience. Cancer Immunology, Immunotherapy, 2015, 64, 1531-1539.	4.2	10
96	Total body photography for skin cancer screening. International Journal of Dermatology, 2015, 54, 1250-1254.	1.0	20
97	Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma. PLoS ONE, 2015, 10, e0138210.	2.5	9
98	Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival. Clinical Cancer Research, 2015, 21, 3879-3887.	7.0	33
99	Vaccines, Adjuvants, and Dendritic Cell Activators—Current Status and Future Challenges. Seminars in Oncology, 2015, 42, 549-561.	2.2	37
100	A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma. Contemporary Clinical Trials, 2015, 41, 172-179.	1.8	21
101	Recent trends in National Institutes of Health funding for surgery: 2003 to 2013. American Journal of Surgery, 2015, 209, 1083-1089.	1.8	83
102	TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10. International Journal of Cancer, 2015, 137, 1386-1396.	5.1	25
103	Peptide Vaccine: Overview. , 2015, , 1-13.		Ο
104	Association of lung adenocarcinoma expression of Trop-2 protein with tumor infiltrating CD8 ⁺ T lymphocytes Journal of Clinical Oncology, 2015, 33, e18509-e18509.	1.6	0
105	A randomized multicenter phase lb/ll study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic cancer Journal of Clinical Oncology, 2015, 33, TPS3098-TPS3098.	1.6	1
106	T cells in the human metastatic melanoma microenvironment express siteâ€specific homing receptors and retention integrins. International Journal of Cancer, 2014, 134, 563-574.	5.1	36
107	A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes. , 2014, 2, 23.		21
108	MHC-Restricted Phosphopeptides from Insulin Receptor Substrate-2 and CDC25b Offer Broad-Based Immunotherapeutic Agents for Cancer. Cancer Research, 2014, 74, 6784-6795.	0.9	28

#	Article	IF	CITATIONS
109	Discussions About Clinical Trials Among Patients With Newly Diagnosed Lung and Colorectal Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	0
110	Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma. , 2014, 2, 11.		173
111	Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunology, Immunotherapy, 2014, 63, 779-786.	4.2	27
112	Inflammatory Adverse Events are Associated with Disease-Free Survival after Vaccine Therapy among Patients with Melanoma. Annals of Surgical Oncology, 2014, 21, 3978-3984.	1.5	7
113	Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma Journal of Clinical Oncology, 2014, 32, 9001-9001.	1.6	40
114	A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence. Cancer Immunology, Immunotherapy, 2013, 62, 1327-1334.	4.2	2
115	Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. Cancer Immunology, Immunotherapy, 2013, 62, 1149-1159.	4.2	44
116	MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab. Journal of Translational Medicine, 2013, 11, 218.	4.4	22
117	Peptide Vaccination in Montanide Adjuvant Induces and GM-CSF Increases CXCR3 and Cutaneous Lymphocyte Antigen Expression by Tumor Antigen–Specific CD8 T Cells. Cancer Immunology Research, 2013, 1, 332-339.	3.4	25
118	Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47). Clinical Cancer Research, 2013, 19, 3611-3620.	7.0	46
119	Surgical Management of the Patient with Metastatic Melanoma to the Heart. Journal of Cardiac Surgery, 2013, 28, 124-128.	0.7	7
120	Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial. Clinical Trials, 2013, 10, 143-150.	1.6	3
121	A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602). Clinical Cancer Research, 2013, 19, 4228-4238.	7.0	98
122	A multipeptide vaccine plus toll-like receptor agonists in melanoma patients, with evaluation of the vaccine site microenvironment and sentinel immunized node (Mel58; NCT01585350) Journal of Clinical Oncology, 2013, 31, TPS3125-TPS3125.	1.6	1
123	Evaluation of the safety and immunogenicity of intratumoral injection of interferon gamma (IFNg) during vaccination in patients with subcutaneous or cutaneous metastases of melanoma (Mel51;) Tj ETQq1 1	0.78 4.3 14 rş	gBTQ/Overlock
124	An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL) Journal of Clinical Oncology, 2013, 31, TPS3114-TPS3114.	1.6	0
125	The Vaccine-site Microenvironment Induced by Injection of Incomplete Freund's Adjuvant, With or Without Melanoma Peptides. Journal of Immunotherapy, 2012, 35, 78-88.	2.4	31
126	Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma. Cancer Research, 2012, 72, 1070-1080.	0.9	461

#	Article	IF	CITATIONS
127	Amelanotic melanomas presenting as red skin lesions: a diagnostic challenge with potentially lethal consequences. International Journal of Dermatology, 2012, 51, 420-426.	1.0	61
128	Surgical resection for bulky or recurrent axillary metastatic melanoma. Journal of Surgical Oncology, 2012, 105, 21-25.	1.7	8
129	The Present and Future of Peptide Vaccines for Cancer. Cancer Journal (Sudbury, Mass), 2011, 17, 343-350.	2.0	248
130	Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Research, 2011, 21, 274-284.	1.2	32
131	Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function. Journal of Translational Medicine, 2011, 9, 26.	4.4	70
132	VEGFRâ€⊋ expression in human melanoma: Revised assessment. International Journal of Cancer, 2011, 129, 2807-2815.	5.1	24
133	Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma. Clinical Cancer Research, 2011, 17, 7440-7450.	7.0	74
134	Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine. Journal of Clinical Oncology, 2011, 29, 2924-2932.	1.6	102
135	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clinical Cancer Research, 2011, 17, 3064-3076.	7.0	108
136	Immunogenicity for CD8+ and CD4+ T Cells of 2 Formulations of an Incomplete Freund's Adjuvant for Multipeptide Melanoma Vaccines. Journal of Immunotherapy, 2010, 33, 630-638.	2.4	22
137	Interferons Induce CXCR3-cognate Chemokine Production by Human Metastatic Melanoma. Journal of Immunotherapy, 2010, 33, 965-974.	2.4	56
138	Interface of Signal Transduction Inhibition and Immunotherapy in Melanoma. Cancer Journal (Sudbury, Mass), 2010, 16, 360-366.	2.0	9
139	Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. Journal of Cutaneous Pathology, 2010, 37, 94-98.	1.3	57
140	Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. Journal of Translational Medicine, 2010, 8, 79.	4.4	38
141	Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial. Clinical Cancer Research, 2009, 15, 7036-7044.	7.0	157
142	Short length of stay and rapid recovery to normal function after surgery for metastatic melanoma to abdominal and retroperitoneal viscera. Journal of Surgical Oncology, 2009, 100, 481-483.	1.7	2
143	Apoptosis of CD4+CD25high T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunology, Immunotherapy, 2009, 58, 867-876.	4.2	33
144	Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies. Vaccine, 2009, 27, 1764-1770.	3.8	20

#	Article	IF	CITATIONS
145	Evaluation of the Sentinel Immunized Node for Immune Monitoring of Cancer Vaccines. Annals of Surgical Oncology, 2008, 15, 3538-3549.	1.5	21
146	Skin Mapping With Punch Biopsies for Defining Margins in Melanoma: When You Don't Know How Far to Go. Annals of Surgical Oncology, 2008, 15, 3028-3035.	1.5	16
147	Human Melanoma Cytolysis by Combined Inhibition of Mammalian Target of Rapamycin and Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor-2. Cancer Research, 2008, 68, 4392-4397.	0.9	35
148	Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens. Journal of Clinical Oncology, 2008, 26, 4973-4980.	1.6	108
149	A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer. Journal of Immunotherapy, 2008, 31, 420-430.	2.4	100
150	Immunology of Cancer. , 2008, , 1947-1963.		0
151	Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting. Clinical Cancer Research, 2007, 13, 6386-6395.	7.0	149
152	Extensive neurocristic hamartoma with skeletal muscle involvement. Journal of Cutaneous Pathology, 2007, 34, 634-639.	1.3	24
153	Immunity to Melanoma Antigens: From Self‶olerance to Immunotherapy. Advances in Immunology, 2006, 90, 243-295.	2.2	55
154	Peptide and Dendritic Cell Vaccines. Clinical Cancer Research, 2006, 12, 2342s-2345s.	7.0	30
155	Defective Human Leukocyte Antigen Class I-associated Antigen Presentation Caused by a Novel β2-Microglobulin Loss-of-function in Melanoma Cells. Journal of Biological Chemistry, 2006, 281, 18763-18773.	3.4	53
156	Autoimmune Toxicities Associated with the Administration of Antitumor Vaccines and Low-Dose Interleukin-2. Journal of Immunotherapy, 2005, 28, 412-419.	2.4	38
157	Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members. Cancer Immunology, Immunotherapy, 2005, 54, 359-371.	4.2	36
158	Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patients. Cancer Immunology, Immunotherapy, 2005, 54, 1095-1105.	4.2	11
159	Interleukin-2 Effects Deserve Further Study: A Need for Better Understanding of Biology and of Optimal Dose Regimens. Journal of Clinical Oncology, 2005, 23, 5267-5268.	1.6	4
160	Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma. Journal of Immunology, 2005, 174, 6863-6871.	0.8	91
161	MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma. Journal of Immunology, 2005, 174, 3080-3086.	0.8	121
162	Progress and controversies in developing cancer vaccines. Journal of Translational Medicine, 2005, 3, 18.	4.4	49

#	Article	IF	CITATIONS
163	Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. Journal of Translational Medicine, 2005, 3, 39.	4.4	105
164	Sentinel Node Assays. , 2005, , 434-444.		0
165	CXC Chemokine Receptor 3 Expression by Activated CD8+ T cells Is Associated with Survival in Melanoma Patients with Stage III Disease. Cancer Research, 2004, 64, 7697-7701.	0.9	127
166	Immunologic and Clinical Outcomes of Vaccination With a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule. Journal of Clinical Oncology, 2004, 22, 4474-4485.	1.6	141
167	Assessment of the Toxicities of Systemic Low-Dose Interleukin-2 Administered in Conjunction with a Melanoma Peptide Vaccine. Journal of Immunotherapy, 2004, 27, 380-388.	2.4	11
168	Preventing the Spontaneous Modification of an HLA-A2-Restricted Peptide at an N-Terminal Glutamine or an Internal Cysteine Residue Enhances Peptide Antigenicity. Journal of Immunotherapy, 2004, 27, 177-183.	2.4	9
169	Competition Among Peptides in Melanoma Vaccines for Binding to MHC Molecules. Journal of Immunotherapy, 2004, 27, 425-431.	2.4	14
170	Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells. Journal of Clinical Oncology, 2003, 21, 4016-4026.	1.6	303
171	Sentinel node biopsy in vulvar and vaginal melanoma: Presentation of six cases and a literature review. Annals of Surgical Oncology, 2002, 9, 840-846.	1.5	70
172	Patient Preferences for Adjuvant Interferon Alfa-2b Treatment. Journal of Clinical Oncology, 2001, 19, 812-823.	1.6	85
173	Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. International Journal of Cancer, 2001, 92, 703-711.	5.1	114
174	Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. , 2001, 92, 703.		1
175	Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clinical Cancer Research, 2001, 7, 3012-24.	7.0	155
176	Melanoma vaccines. Current Opinion in Oncology, 2000, 12, 163-173.	2.4	39
177	Pseudomonas Exotoxin-Mediated Delivery of Exogenous Antigens to MHC Class I and Class II Processing Pathways. Cellular Immunology, 2000, 203, 75-83.	3.0	18
178	Vaccination for melanoma. Current Oncology Reports, 2000, 2, 292-299.	4.0	8
179	Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunology, Immunotherapy, 2000, 48, 661-672.	4.2	89
180	Terminal modifications inhibit proteolytic degradation of an immunogenic mart-127-35 peptide: Implications for peptide vaccines. International Journal of Cancer, 1999, 83, 326-334.	5.1	152

#	ARTICLE	IF	CITATIONS
181	Tumor antigens and tumor vaccines: Peptides as immunogens. , 1996, 12, 446-453.		40
182	The annual risk of melanoma progression. Implications for the concept of cure. Cancer, 1992, 70, 1917-1927.	4.1	69
183	Inhibition of the growth of human melanoma xenografts in nude mice by human tumor-specific cytotoxic T-cells. Journal of Surgical Oncology, 1990, 43, 67-72.	1.7	5
184	Acral with melanoma: A review of 185 patients identification of prognostic variables. Journal of Surgical Oncology, 1990, 45, 91-98.	1.7	111
185	Melanoma-Specific Cytotoxic T Cells Generated from Peripheral Blood Lymphocytes. Annals of Surgery, 1989, 210, 194-202.	4.2	19
186	Autologous lymph node cell-derived tumor-specific cytotoxic t-cells for use in adoptive immunotherapy of human melanoma. Cancer, 1988, 62, 84-91.	4.1	30
187	Immune Mechanisms Orchestrate Tertiary Lymphoid Structures in Tumors Via Cancer-Associated Fibroblasts. SSRN Electronic Journal, 0, , .	0.4	4